antiplatelets drug

Description Results NMA

Vasc events 0.23 [0.03; 1.92]

Major bleeds NaN [NaN; NaN]

Vasc deaths 0.31 [0.03; 2.76]

Non-fatal stroke NaN [NaN; NaN]

Non-fatal MI 0.00 [0.00; NaN]

Non vasc deaths NaN [NaN; NaN]

cardiovascular events 0.23 [0.03; 1.92]

Vasc events 0.61 [0.43; 0.88]

Non-fatal MI 0.56 [0.36; 0.89]

cardiovascular events 0.61 [0.43; 0.88]

Major bleeds NaN [NaN; NaN]

Vasc deaths 0.64 [0.34; 1.21]

Non-fatal stroke 1.54 [0.26; 9.17]

Non vasc deaths NaN [NaN; NaN]

Vasc events 0.90 [0.56; 1.45]

Major bleeds NaN [NaN; NaN]

Vasc deaths 0.72 [0.38; 1.35]

Non-fatal stroke ∞ [NaN; ∞]

Non-fatal MI 1.15 [0.50; 2.60]

Non vasc deaths ∞ [NaN; ∞]

cardiovascular events 0.90 [0.56; 1.45]

Vasc events 0.53 [0.38; 0.74]

Non-fatal MI 0.52 [0.35; 0.76]

cardiovascular events 0.53 [0.38; 0.74]

Major bleeds NaN [NaN; NaN]

Vasc deaths 0.56 [0.25; 1.25]

Non-fatal stroke NaN [NaN; NaN]

Non vasc deaths 0.99 [0.14; 7.03]

Vasc events 3.50 [0.45; 27.07]

Major bleeds NaN [NaN; NaN]

Vasc deaths 0.50 [0.03; 7.70]

Non-fatal stroke ∞ [NaN; ∞]

Non-fatal MI ∞ [NaN; ∞]

Non vasc deaths NaN [NaN; NaN]

cardiovascular events 3.50 [0.45; 27.07]

Non-fatal MI 0.28 [0.09; 0.82]

fatal and non fatal MI 0.28 [0.09; 0.82]

Vasc events 0.63 [0.38; 1.04]

cardiovascular events 0.63 [0.38; 1.04]

refractory ischemia 0.72 [0.43; 1.21]

Vasc events 0.00 [0.00; NaN]

Major bleeds NaN [NaN; NaN]

Vasc deaths 0.00 [0.00; NaN]

Non-fatal MI 0.00 [0.00; NaN]

Non vasc deaths NaN [NaN; NaN]

cardiovascular events 0.00 [0.00; NaN]

vascular death 0.75 [0.35; 1.62]

non fatla stroke ∞ [NaN; ∞]

non fatal MI 0.33 [0.07; 1.57]

vascular events 0.67 [0.36; 1.23]

non vascular death NaN [NaN; NaN]

vascular death 0.70 [0.43; 1.14]

major bleeding 0.98 [0.06; 15.56]

non fatla stroke 0.49 [0.04; 5.36]

non fatal MI 0.76 [0.29; 2.02]

vascular events 0.70 [0.46; 1.07]

non vascular death NaN [NaN; NaN]

vascular death 0.80 [0.73; 0.87]

non fatla stroke 0.56 [0.35; 0.88]

non fatal MI 0.46 [0.35; 0.61]

vascular events 0.74 [0.68; 0.80]

major bleeding 1.34 [0.73; 2.46]

non vascular death 0.29 [0.06; 1.38]

vascular death NaN [NaN; NaN]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events NaN [NaN; NaN]

non vascular death 0.00 [0.00; NaN]

vascular death 1.12 [0.07; 16.98]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events 1.12 [0.07; 16.98]

non vascular death NaN [NaN; NaN]

non fatal MI 0.27 [0.08; 0.94]

vascular events 0.30 [0.10; 0.89]

vascular death 0.44 [0.04; 4.82]

non fatla stroke NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

Aspirin 324 mg/d (n=26)

vs.

(n=24)

Sample size: 26/24

Primary endpoint:

FU duration: 3m

Aspirin 324mg/d (n=661)

vs.

placebo (n=677)

double blind

Sample size: 661/677

Primary endpoint:

FU duration: 3m

Aspirin 1300mg/d + sulfinpyrazone 800mg/d (n=416)

vs.

placebo (n=139)

double blind

Sample size: 416/139

Primary endpoint:

FU duration: 18m

Aspirin 75mg/d (n=474)

vs.

placebo (n=471)

half of the patients received heparin in a 2x2 factorial design

double blind

Factorial plan

Sample size: 474/471

Primary endpoint:

FU duration: 12m

Aspirin 325mg/d, Aspirin 40mg/d (n=56)

vs.

(n=28)

Sample size: 56/28

Primary endpoint:

FU duration: 12m

Aspirin 325 mg twice daily (n=121)

vs.

placebo (n=118)

double blind

Sample size: 121/118

Primary endpoint:

FU duration: 6d (3m)

Aspirin 80mg/d (Heparin + Warfarin) (n=37)

vs.

full-dose heparin followed by warfarin (n=24)

Sample size: 37/24

Primary endpoint:

FU duration: 3m

aspirin (100 mg/day) for 3 months (n=50)

vs.

placebo (n=50)

double blind

Parallel groups

Sample size: 50/50

Primary endpoint:

FU duration: 3m

aspirin (325 mg on alternate days for 28 days) (n=313)

vs.

placebo (n=306)

double blind

Parallel groups

Sample size: 313/306

Primary endpoint:

FU duration: 1m

160 mg/day enteric-coated aspirin for one month (n=8587)

vs.

placebo (n=8600)

double blind

Parallel groups

Sample size: 8587/8600

Primary endpoint:

FU duration: 35d

aspirin 500mg/d starting 12 h after admissionand and then intermittently every third day for one month (n=10)

vs.

no aspirin (n=10)

open

Parallel groups

Sample size: 10/10

Primary endpoint:

FU duration: 30d (12m)

A1320 + D300, A1320 (n=25)

vs.

(n=28)

Parallel groups

Sample size: 25/28

Primary endpoint:

FU duration: 14d

325 mg aspirin daily with discontinuation of heparin (n=107)

vs.

placebo (n=95)

double blind

Parallel groups

Sample size: 107/95

Primary endpoint: patency of the infarct related artery

FU duration: 3m

Aspirin 1300mg/d (n=-9)

vs.

placebo (n=139)

double blind

Sample size: -9/139

Primary endpoint:

FU duration: 18m

400-mg loading dose of atopaxar followed by a daily dose of 50 mg, 100 mg, or 200 mg for 12 weeks (n=603)

vs.

placebo (n=0)

Parallel groups

Sample size: 603/0

Primary endpoint:

FU duration:

pahse 2

atopaxar at a loading dose of 400 mg followed by 50 mg per day, 100 mg per day, or 200 mg per day for 12 weeks (n=-9)

vs.

atopaxar at a loading dose of 400 mg followed by placebo (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint: bleeding events

FU duration:

phase 2 study

non fatal MI 0.82 [0.70; 0.96]

vascular events 0.92 [0.87; 0.97]

non fatla stroke 0.89 [0.70; 1.13]

clopidogrel 75 mg daily (n=22961)

vs.

placebo (n=22891)

double-blind

Parallel groups

Sample size: 22961/22891

Primary endpoint: death, reinfarction, or stroke

FU duration: until discharge or up to 4 wee

clopidogrel (300-mg loading dose, followed by 75 mg once daily) (n=-9)

vs.

placebo (n=-9)

double blind

Sample size: -9/-9

Primary endpoint: death, reMI, occlusion

FU duration: 30 days

Vasc events 0.82 [0.73; 0.90]

fatal and non fatal MI 0.78 [0.68; 0.90]

cardiovascular events 0.82 [0.73; 0.90]

Major bleeds 1.38 [1.13; 1.67]

Vasc deaths 0.93 [0.80; 1.08]

Non vasc deaths 0.92 [0.60; 1.40]

fatala and non fatal stroke 0.87 [0.64; 1.18]

refractory ischemia 0.93 [0.83; 1.04]

fatal bleeding 0.74 [0.34; 1.61]

clopidogrel 300 mg immediately, followed by 75 mg once daily + aspirin for 3 to 12 months (n=6259)

vs.

aspirin (+placebo) (n=6303)

double blind

Parallel groups

Sample size: 6259/6303

Primary endpoint: CV death, MI, stroke

FU duration: NA (median <9 months)

Major bleeds 1.24 [1.05; 1.46]

vascular death, MI, stroke 0.94 [0.83; 1.06]

Severe recurrent ischemia 0.93 [0.64; 1.36]

Hemorrhagic stoke 0.67 [0.19; 2.37]

Vasc events 0.94 [0.84; 1.06]

all cause death 0.96 [0.82; 1.13]

Vasc deaths 0.95 [0.81; 1.13]

fatala and non fatal stroke 0.99 [0.70; 1.39]

fatal and non fatal MI 0.86 [0.72; 1.02]

cardiovascular events 0.94 [0.84; 1.06]

fatal bleeding 1.07 [0.53; 2.16]

Double-dose clopidogrel (n=12520)

vs.

Standard-dose clopidogrel (n=12566)

patients were also assigned in an open-label manner to 300 to 325 mg of aspirin once daily or 75- to 100-mg aspirin once daily

about two thirds eventually underwent PCI (although PCI was planned for everyone who was randomized, about a third of the patients did not undergo the procedure because they were not considered suitable based on angiography findings)

open

Factorial plan

Sample size: 12520/12566

Primary endpoint: CV death/MI/stroke

FU duration: 30 days

Vasc events 0.55 [0.22; 1.35]

Major bleeds NaN [NaN; NaN]

Vasc deaths ∞ [NaN; ∞]

Non-fatal stroke NaN [NaN; NaN]

Non-fatal MI 0.45 [0.17; 1.20]

Non vasc deaths ∞ [NaN; ∞]

cardiovascular events 0.55 [0.22; 1.35]

Aspirin 50mg/d + Dipyridamol 400mg/d (n=44)

vs.

placebo (n=44)

double blind

Sample size: 44/44

Primary endpoint:

FU duration: 12m

major bleeding NaN [NaN; NaN]

non fatla stroke ∞ [NaN; ∞]

non fatal MI NaN [NaN; NaN]

elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus (n=34)

vs.

placebo (n=36)

5 arms: 4 doses of elinogrel or placebo before the start of the diagnostic angiogram preceding primary PCI

double blind

Parallel groups

Sample size: 34/36

Primary endpoint: TIMI and ST resolution

FU duration: 30-37 days

phase IIb (dose-escalation study)

all cause death 0.94 [0.82; 1.08]

all bleeding (major and minor) 1.26 [0.94; 1.69]

Major bleeds 1.21 [0.83; 1.77]

Vasc deaths 0.93 [0.80; 1.08]

fatala and non fatal stroke 0.90 [0.64; 1.26]

fatal and non fatal MI 0.96 [0.84; 1.10]

fatal bleeding 0.78 [0.29; 2.09]

death, MI, stroke 0.96 [0.87; 1.06]

Vasc events 0.82 [0.74; 0.91]

revascularization 0.67 [0.55; 0.82]

Non-fatal MI 0.76 [0.68; 0.86]

all bleeding (major and minor) 1.31 [1.11; 1.55]

Major bleeds 1.31 [1.03; 1.68]

fatal bleeding 4.19 [1.58; 11.10]

all cause death 0.95 [0.78; 1.16]

Vasc deaths 0.88 [0.70; 1.11]

Non-fatal stroke 1.01 [0.71; 1.45]

prasugrel 10 mg daily (n=4663)

vs.

clopidogrel 75 mg daily (n=4663)

double-blind

Parallel groups

Sample size: 4663/4663

Primary endpoint: cardiovascular events

FU duration: 17 months (median)

prasugrel 60-mg loading dose and 10-mg daily maintenance dose, for 6 to 15 months (n=6813)

vs.

clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) for 6 to 15 months (n=6795)

double blind

Parallel groups

Sample size: 6813/6795

Primary endpoint: cardiovascular death, nonfatal MI, or nonfatal

FU duration:

vascular death 0.50 [0.10; 2.61]

major bleeding NaN [NaN; NaN]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events 0.50 [0.10; 2.61]

non vascular death NaN [NaN; NaN]

vascular death 5.00 [0.61; 41.25]

vascular events 5.00 [0.61; 41.25]

non vascular death NaN [NaN; NaN]

vascular death ∞ [NaN; ∞]

vascular events ∞ [NaN; ∞]

non vascular death NaN [NaN; NaN]

S (W) (n=50)

vs.

(n=50)

Parallel groups

Sample size: 50/50

Primary endpoint:

FU duration: 21d

Sulphinpyrazone 200 mg four times daily (n=49)

vs.

placebo (n=49)

Parallel groups

Sample size: 49/49

Primary endpoint:

FU duration: 10d

sulphinpyrazone, 4 x 200 mg daily for 7 days (n=15)

vs.

placebo (n=14)

double blind

Parallel groups

Sample size: 15/14

Primary endpoint: renal function

FU duration: 7d

sulfinpyrazone 800mg/d (n=-9)

vs.

placebo (n=139)

double blind

Sample size: -9/139

Primary endpoint:

FU duration: 18m

vascular death, MI, stroke 0.85 [0.78; 0.92]

Vasc events 0.88 [0.82; 0.95]

all cause death 0.78 [0.69; 0.89]

Vasc deaths 0.80 [0.69; 0.91]

fatal and non fatal MI 0.85 [0.75; 0.95]

cardiovascular events 0.85 [0.78; 0.92]

death, MI, stroke 0.84 [0.77; 0.92]

Severe recurrent ischemia 0.87 [0.75; 1.01]

Hemorrhagic stoke 1.76 [0.89; 3.47]

all bleeding (major and minor) 1.04 [0.95; 1.13]

Major bleeds 1.03 [0.92; 1.14]

Ischemic stroke 1.05 [0.79; 1.40]

Non vasc deaths 0.72 [0.49; 1.04]

fatala and non fatal stroke 1.17 [0.91; 1.52]

fatal bleeding 0.87 [0.48; 1.58]

Vasc events 1.09 [0.58; 2.07]

all cause death 1.37 [0.44; 4.27]

all bleeding (major and minor) 1.11 [0.70; 1.77]

Major bleeds 0.98 [0.58; 1.65]

Vasc deaths 1.47 [0.42; 5.16]

fatala and non fatal stroke 1.96 [0.18; 21.49]

fatal and non fatal MI 0.78 [0.37; 1.65]

cardiovascular events 1.09 [0.58; 2.07]

ticagrelor 90mg twice daily (n=9333)

vs.

clopidogrel 75mg once daily (n=9291)

Patients undergoing PCI after randomization received, in a blind fashion, an additional dose of their study drug at the time of PCI

double blind

Parallel groups

Sample size: 9333/9291

Primary endpoint: Cv death, MI, stroke

FU duration: 1 y

ticagrelor 90 mg twice daily (n=334)

vs.

clopidogrel (n=327)

3 arms trial: AZD6140 90 mg and 180mg twice daily, Clopidogrel 75 mg daily

double blind

Parallel groups

Sample size: 334/327

Primary endpoint: major or minor bleeding through 4 weeks

FU duration: 12 weeks

Vasc events 0.52 [0.32; 0.83]

Non-fatal MI 0.54 [0.30; 0.98]

cardiovascular events 0.52 [0.32; 0.83]

Major bleeds NaN [NaN; NaN]

Vasc deaths 0.54 [0.23; 1.24]

Non-fatal stroke 0.00 [0.00; NaN]

Non vasc deaths NaN [NaN; NaN]

Vasc events 1.00 [0.17; 5.98]

Major bleeds NaN [NaN; NaN]

Vasc deaths NaN [NaN; NaN]

Non-fatal stroke NaN [NaN; NaN]

Non-fatal MI 1.00 [0.17; 5.98]

Non vasc deaths NaN [NaN; NaN]

cardiovascular events 1.00 [0.17; 5.98]

vascular death NaN [NaN; NaN]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

ticlopidine 250 mg b.i.d (n=314)

vs.

untreated control (n=338)

single blind

Sample size: 314/338

Primary endpoint:

FU duration: 6m

Ticlopidine 500mg/d (n=12)

vs.

(n=12)

Sample size: 12/12

Primary endpoint:

FU duration: 14d

ticlopidine 500mg/d (n=24)

vs.

placebo (n=19)

double blind

Parallel groups

Sample size: 24/19

Primary endpoint:

FU duration: 3m

Vasc events 0.21 [0.05; 0.91]

cardiovascular events 0.21 [0.05; 0.91]

Vasc deaths 0.21 [0.02; 1.72]

Non-fatal MI 0.21 [0.02; 1.72]

trapidil (n=71)

vs.

(n=73)

Sample size: 71/73

Primary endpoint:

FU duration: 6m

Non-fatal MI 0.34 [0.14; 0.84]

Vasc events 0.45 [0.20; 1.02]

revascularization 0.83 [0.51; 1.35]

Major bleeds NaN [NaN; NaN]

Vasc deaths ∞ [NaN; ∞]

Non vasc deaths NaN [NaN; NaN]

cardiovascular events 0.45 [0.20; 1.02]

triflusal 300 mg three times daily (n=143)

vs.

placebo (n=138)

double blind

Parallel groups

Sample size: 143/138

Primary endpoint:

FU duration: 6m

vorapaxar (SCH 530348) oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year (n=-9)

vs.

Placebo (added to the existing standard of care (eg, aspirin, clopidogrel) (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: CV death, MI, stroke, recurrent ischaemia, urgent revasc

FU duration:

vascular death 0.75 [0.35; 1.62]

non fatla stroke ∞ [NaN; ∞]

non fatal MI 0.33 [0.07; 1.57]

vascular events 0.67 [0.36; 1.23]

non vascular death NaN [NaN; NaN]

vascular death 0.70 [0.43; 1.14]

major bleeding 0.98 [0.06; 15.56]

non fatla stroke 0.49 [0.04; 5.36]

non fatal MI 0.76 [0.29; 2.02]

vascular events 0.70 [0.46; 1.07]

non vascular death NaN [NaN; NaN]

vascular death 0.80 [0.73; 0.87]

non fatla stroke 0.56 [0.35; 0.88]

non fatal MI 0.46 [0.35; 0.61]

vascular events 0.74 [0.68; 0.80]

major bleeding 1.34 [0.73; 2.46]

non vascular death 0.29 [0.06; 1.38]

vascular death NaN [NaN; NaN]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events NaN [NaN; NaN]

non vascular death 0.00 [0.00; NaN]

vascular death 1.12 [0.07; 16.98]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events 1.12 [0.07; 16.98]

non vascular death NaN [NaN; NaN]

non fatal MI 0.27 [0.08; 0.94]

vascular events 0.30 [0.10; 0.89]

vascular death 0.44 [0.04; 4.82]

non fatla stroke NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

aspirin (100 mg/day) for 3 months (n=50)

vs.

placebo (n=50)

double blind

Parallel groups

Sample size: 50/50

Primary endpoint:

FU duration: 3m

aspirin (325 mg on alternate days for 28 days) (n=313)

vs.

placebo (n=306)

double blind

Parallel groups

Sample size: 313/306

Primary endpoint:

FU duration: 1m

160 mg/day enteric-coated aspirin for one month (n=8587)

vs.

placebo (n=8600)

double blind

Parallel groups

Sample size: 8587/8600

Primary endpoint:

FU duration: 35d

aspirin 500mg/d starting 12 h after admissionand and then intermittently every third day for one month (n=10)

vs.

no aspirin (n=10)

open

Parallel groups

Sample size: 10/10

Primary endpoint:

FU duration: 30d (12m)

A1320 + D300, A1320 (n=25)

vs.

(n=28)

Parallel groups

Sample size: 25/28

Primary endpoint:

FU duration: 14d

325 mg aspirin daily with discontinuation of heparin (n=107)

vs.

placebo (n=95)

double blind

Parallel groups

Sample size: 107/95

Primary endpoint: patency of the infarct related artery

FU duration: 3m

non fatal MI 0.82 [0.70; 0.96]

vascular events 0.92 [0.87; 0.97]

non fatla stroke 0.89 [0.70; 1.13]

clopidogrel 75 mg daily (n=22961)

vs.

placebo (n=22891)

double-blind

Parallel groups

Sample size: 22961/22891

Primary endpoint: death, reinfarction, or stroke

FU duration: until discharge or up to 4 wee

clopidogrel (300-mg loading dose, followed by 75 mg once daily) (n=-9)

vs.

placebo (n=-9)

double blind

Sample size: -9/-9

Primary endpoint: death, reMI, occlusion

FU duration: 30 days

major bleeding NaN [NaN; NaN]

non fatla stroke ∞ [NaN; ∞]

non fatal MI NaN [NaN; NaN]

elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus (n=34)

vs.

placebo (n=36)

5 arms: 4 doses of elinogrel or placebo before the start of the diagnostic angiogram preceding primary PCI

double blind

Parallel groups

Sample size: 34/36

Primary endpoint: TIMI and ST resolution

FU duration: 30-37 days

phase IIb (dose-escalation study)

vascular death 0.50 [0.10; 2.61]

major bleeding NaN [NaN; NaN]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events 0.50 [0.10; 2.61]

non vascular death NaN [NaN; NaN]

vascular death 5.00 [0.61; 41.25]

vascular events 5.00 [0.61; 41.25]

non vascular death NaN [NaN; NaN]

vascular death ∞ [NaN; ∞]

vascular events ∞ [NaN; ∞]

non vascular death NaN [NaN; NaN]

S (W) (n=50)

vs.

(n=50)

Parallel groups

Sample size: 50/50

Primary endpoint:

FU duration: 21d

Sulphinpyrazone 200 mg four times daily (n=49)

vs.

placebo (n=49)

Parallel groups

Sample size: 49/49

Primary endpoint:

FU duration: 10d

sulphinpyrazone, 4 x 200 mg daily for 7 days (n=15)

vs.

placebo (n=14)

double blind

Parallel groups

Sample size: 15/14

Primary endpoint: renal function

FU duration: 7d

vascular death NaN [NaN; NaN]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

ticlopidine 500mg/d (n=24)

vs.

placebo (n=19)

double blind

Parallel groups

Sample size: 24/19

Primary endpoint:

FU duration: 3m

vascular death 0.36 [0.04; 3.40]

Non fatal stroke NaN [NaN; NaN]

non fatal MI 0.00 [0.00; NaN]

non vascular death NaN [NaN; NaN]

vascular event 0.22 [0.03; 1.81]

vascular death 1.07 [0.16; 7.10]

Non fatal stroke 0.00 [0.00; NaN]

non fatal MI 0.00 [0.00; NaN]

non vascular death NaN [NaN; NaN]

vascular event 0.53 [0.11; 2.70]

vascular death 2.59 [0.93; 7.18]

non vascular death NaN [NaN; NaN]

vascular event 2.59 [0.93; 7.18]

aspirin 1200 (n=71)

vs.

placebo (n=77)

double blind

Sample size: 71/77

Primary endpoint:

FU duration: 22m

aspirin 100 mg/d (n=29)

vs.

placebo (n=31)

double blind

Sample size: 29/31

Primary endpoint:

FU duration: 4m

aspirin 150 mg daily (n=373)

vs.

placebo (n=371)

3 arms trials: placebo, aspirin, aspirin + dipyridamole

double blind

Parallel groups

Sample size: 373/371

Primary endpoint:

FU duration: 28d

aspirin 324 mg daily (n=127)

vs.

placebo (n=110)

double blind

Sample size: 127/110

Primary endpoint:

FU duration: 12m

aspirin 100 (n=72)

vs.

placebo (n=72)

double blind

Sample size: 72/72

Primary endpoint:

FU duration: 6m

aspirin 162 mg plus clopidogrel 75 mg daily for 1 year (n=56)

vs.

aspirin 162 mg plus placebo daily (n=57)

double blind

Parallel groups

Sample size: 56/57

Primary endpoint: vein graft intimal area

FU duration: 1 y

vascular death 1.81 [0.61; 5.36]

vascular event 1.81 [0.61; 5.36]

aspirin 50 mg + dipyridamole 75mg 3 times daily (n=368)

vs.

placebo (n=371)

3 arms trials: placebo, aspirin, aspirin + dipyridamole

double blind

Parallel groups

Sample size: 368/371

Primary endpoint:

FU duration: 28d

vascular death 2.00 [0.61; 6.51]

non vascular death NaN [NaN; NaN]

vascular event 2.00 [0.61; 6.51]

vascular death 0.85 [0.26; 2.73]

vascular event 0.85 [0.26; 2.73]

vascular death NaN [NaN; NaN]

Non fatal stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

vascular event NaN [NaN; NaN]

vascular death 2.13 [0.20; 23.06]

Non fatal stroke 1.06 [0.07; 16.75]

non vascular death NaN [NaN; NaN]

vascular event 1.59 [0.27; 9.33]

vascular death ∞ [NaN; ∞]

Non fatal stroke 0.00 [0.00; NaN]

non fatal MI 0.52 [0.05; 5.38]

non vascular death NaN [NaN; NaN]

vascular event 0.69 [0.13; 3.80]

vascular death NaN [NaN; NaN]

non fatal MI 0.00 [0.00; NaN]

non vascular death NaN [NaN; NaN]

vascular event 0.00 [0.00; NaN]

aspirin 990 mg and dipyridamole 225 mg daily (n=160)

vs.

placebo (n=160)

double blind

Sample size: 160/160

Primary endpoint:

FU duration: 12m

aspirin 975 + dipiridamol 225 (n=202)

vs.

placebo (n=205)

double blind

Sample size: 202/205

Primary endpoint:

FU duration: 12m

aspirin 325 mg three times a day + dipyridamole 75 mg three times a day (n=18)

vs.

control (n=30)

open

Sample size: 18/30

Primary endpoint:

FU duration: 6m

aspirin 975 mg/d + dipiridamol 225 mg/d, aspirin 975 mg/d (n=96)

vs.

placebo (n=102)

double blind

Sample size: 96/102

Primary endpoint:

FU duration: 12m

aspirin 200 + dipiridamol 400 (H) (n=24)

vs.

(n=25)

Sample size: 24/25

Primary endpoint:

FU duration: 12m

aspirin 50 + dipiridamol 400 (n=62)

vs.

placebo (n=63)

double blind

Sample size: 62/63

Primary endpoint:

FU duration: 9m

aspirin 990 + dipiridamol 225 (W) (n=61)

vs.

placebo (n=64)

double blind

Sample size: 61/64

Primary endpoint:

FU duration: 6m

aspirin 1000 + dipiridamol 225 (n=47)

vs.

control (no medication) (n=46)

open

Sample size: 47/46

Primary endpoint:

FU duration: 12m

aspirin 975 + dipiridamol 225 (n=34)

vs.

placebo (n=35)

double blind

Sample size: 34/35

Primary endpoint:

FU duration: 3m

aspirin 20 + dipiridamol 100 (n=60)

vs.

(n=54)

Sample size: 60/54

Primary endpoint:

FU duration: 12m

dipiridamol 400 (n=20)

vs.

control (n=20)

Sample size: 20/20

Primary endpoint:

FU duration: 48h

dipiridamol 100 mg orally q.i.d. (n=174)

vs.

placebo (n=186)

double blind

Sample size: 174/186

Primary endpoint:

FU duration: 12m

sulfinpyrazone 800 mg/day (n=130)

vs.

placebo (n=125)

double blind

Sample size: 130/125

Primary endpoint:

FU duration: 10d

ST (n=90)

vs.

(n=85)

Sample size: 90/85

Primary endpoint:

FU duration: 21d

vascular death 0.00 [0.00; NaN]

Non fatal stroke 0.00 [0.00; NaN]

non fatal MI NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

vascular event 0.00 [0.00; NaN]

vascular death 1.98 [0.18; 21.41]

Non fatal stroke 0.00 [0.00; NaN]

non fatal MI 0.33 [0.03; 3.11]

non vascular death 0.00 [0.00; NaN]

vascular event 0.49 [0.13; 1.91]

ticlopidine 250 mg twice daily (n=75)

vs.

placebo (n=75)

double blind

Sample size: 75/75

Primary endpoint:

FU duration: 3m

ticlopidine 250 mg twice daily (n=88)

vs.

placebo (n=87)

double blind

Sample size: 88/87

Primary endpoint:

FU duration: 12m

ticlopidine 500 (NC) (n=50)

vs.

(n=50)

Sample size: 50/50

Primary endpoint:

FU duration: 3m

ticlopidine 500 (n=9)

vs.

(n=10)

Sample size: 9/10

Primary endpoint:

FU duration: 6m

ticlopidine 500 (n=20)

vs.

(n=20)

Sample size: 20/20

Primary endpoint:

FU duration: 3m (12m)

ticlopidine 500 (n=21)

vs.

(n=24)

Sample size: 21/24

Primary endpoint:

FU duration: 14d

Cv death 0.88 [0.79; 0.98]

CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.88 [0.79; 0.98]

major bleeding 1.29 [1.09; 1.52]

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Total mortality 0.70 [0.48; 1.01]

Cardiovascular death 0.70 [0.47; 1.02]

Non-fatal MI 0.89 [0.54; 1.46]

Total mortality 0.74 [0.52; 1.05]

Total mortality 0.83 [0.65; 1.05]

Cardiovascular death 0.50 [0.27; 0.92]

Fatal MI 0.38 [0.17; 0.85]

Non-fatal MI 0.47 [0.29; 0.75]

Total mortality 0.68 [0.44; 1.05]

Non-fatal MI 0.78 [0.63; 0.96]

Total mortality 1.11 [0.94; 1.32]

Total mortality 0.82 [0.51; 1.34]

Fatal MI 0.49 [0.17; 1.41]

Non-fatal MI 0.71 [0.33; 1.53]

Total mortality 0.82 [0.59; 1.13]

Cardiovascular death 0.82 [0.58; 1.17]

Non-fatal MI 0.70 [0.48; 1.03]

Non-fatal MI 0.27 [0.10; 0.72]

Total mortality 1.18 [0.45; 3.12]

Cardiovascular death 1.10 [0.34; 3.57]

Non fatal MI 0.67 [0.45; 0.98]

vascular event 0.71 [0.57; 0.89]

vascular death 0.76 [0.54; 1.07]

Non fatal stroke 0.79 [0.45; 1.39]

non vascular death 1.66 [0.79; 3.51]

All cause mortality 0.93 [0.72; 1.21]

CHD death 1.35 [0.82; 2.21]

CHD events (fatal and non fatal) 1.10 [0.83; 1.45]

CV death 1.23 [0.80; 1.89]

fatal MI 1.35 [0.82; 2.21]

fatal stroke 0.89 [0.35; 2.29]

non fatal MI 0.98 [0.69; 1.40]

stroke (fatal and non fatal) 0.74 [0.49; 1.12]

CV events (fatal and non fatal) 0.99 [0.79; 1.25]

peripheral artery disease 0.91 [0.70; 1.17]

stable angina 0.90 [0.66; 1.22]

CV death 0.10 [0.01; 0.79]

CHD death 0.00 [0.00; NaN]

CHD events (fatal and non fatal) 0.81 [0.50; 1.32]

fatal MI 0.00 [0.00; NaN]

fatal stroke 0.20 [0.02; 1.73]

non fatal MI 1.35 [0.57; 3.19]

stroke (fatal and non fatal) 0.89 [0.54; 1.46]

CV events (fatal and non fatal) 0.80 [0.59; 1.09]

peripheral artery disease 0.64 [0.25; 1.66]

stable angina 1.10 [0.49; 2.49]

unstable angina 0.40 [0.13; 1.29]

non fatal MI 4.20 [1.10; 16.10]

All cause mortality 0.49 [0.13; 1.95]

CV death 0.49 [0.10; 2.42]

CV events (fatal and non fatal) 1.48 [0.68; 3.22]

CHD events (fatal and non fatal) 0.85 [0.73; 1.00]

All cause mortality 0.93 [0.81; 1.06]

CV death 0.92 [0.79; 1.07]

non fatal MI 0.78 [0.54; 1.11]

stroke (fatal and non fatal) 1.18 [0.88; 1.58]

CV events (fatal and non fatal) 0.95 [0.83; 1.07]

Evénements vasculaires 0.42 [0.22; 0.80]

IDM totaux 0.18 [0.04; 0.79]

Mortalité totale 1.71 [0.51; 5.75]

IDM fatal 0.98 [0.14; 6.87]

Mortalité vasculaire 1.22 [0.33; 4.48]

AVC fatal 1.96 [0.18; 21.39]

AVC non fatal 0.33 [0.07; 1.59]

IDM non fatal 0.00 [0.00; NaN]

CHD events (fatal and non fatal) 0.40 [0.20; 0.79]

All cause mortality 1.23 [0.69; 2.19]

CHD events (fatal and non fatal) 0.49 [0.17; 1.43]

CV death 1.23 [0.49; 3.10]

revascularization procedure 0.79 [0.31; 1.98]

stroke (fatal and non fatal) 0.89 [0.36; 2.17]

all MI 0.49 [0.17; 1.43]

CV events (fatal and non fatal) 0.90 [0.50; 1.62]

peripheral artery disease 0.83 [0.38; 1.85]

stable angina 0.80 [0.39; 1.65]

stroke (fatal and non fatal) 0.48 [0.26; 0.88]

CHD events (fatal and non fatal) 1.50 [0.91; 2.47]

all MI 1.50 [0.91; 2.47]

CV events (fatal and non fatal) 0.93 [0.67; 1.31]

Aspirin (324 mg) 3x/d (n=758)

vs.

Placebo (n=771)

Double blind

Parallel groups

Sample size: 758/771

Primary endpoint: No primary outcome clearly defined

FU duration: 1.83 y

Aspirin (300 mg) 1x/d (n=615)

vs.

Placebo (n=624)

Double blind

Parallel groups

Sample size: 615/624

Primary endpoint: Total mortality

FU duration: 2 years

Aspirin (300 mg) 3x/d for one year (n=832)

vs.

Placebo (n=850)

Double blind

Parallel groups

Sample size: 832/850

Primary endpoint: Total mortality

FU duration: 1 y

Aspirin (1.5 g daily) on an average period of 22 months (n=672)

vs.

Placebo (n=668)

Double blind

Parallel groups

Sample size: 672/668

Primary endpoint: Death or reinfraction

FU duration: 1.75 y (mean)

Aspirin (500 mg) 2x/d for at least 3 years (n=2267)

vs.

Placebo (n=2257)

Double blind

Parallel groups

Sample size: 2267/2257

Primary endpoint: Total mortality

FU duration: > 3 y

Aspirin (500 mg) 3x/d for 2 years (n=317)

vs.

Placebo (n=309)

Double blind

Parallel groups

Sample size: 317/309

Primary endpoint: No primary outcome clearly defined

FU duration: 2 y

part of a 3-group trial

Aspirin (324 mg) 3x/d (n=810)

vs.

Placebo (n=406)

Double blind

Parallel groups

Sample size: 810/406

Primary endpoint: No primary outcome clearly defined

FU duration: 41 mo

part of 3-group trial

Aspirin (81 mg) 1x/d (n=250)

vs.

No antiplatelets (n=230)

Open

Parallel groups

Sample size: 250/230

Primary endpoint: No primary outcome clearly defined

FU duration: 1.3 y (mean)

part of a 3-group trial

groupe 1 : Aspirine 990 mg / j (pour mémoire : groupe 2 : Aspirine 990 mg / j + dipyridamole 225 mg/j) (n=100)

vs.

Placebo (n=100)

Données isuues de la méta-analyse ATC

double blind

Parallel groups

Sample size: 100/100

Primary endpoint: Progression de l’athérosclérose

FU duration: <5 y

groupe 1 : Aspirine 330 mg / j (pour mémoire : groupe 2 : Aspirine 330 mg / j + dipyridamole 75 mg / j) (n=80)

vs.

Placebo (n=80)

single blind

Parallel groups

Sample size: 80/80

Primary endpoint: Score de progression de l’athérosclérose

FU duration:

Aspirine: 1500 mg / jour (n=92)

vs.

Placebo (n=84)

double blind

Parallel groups

Sample size: 92/84

Primary endpoint:

FU duration:

Aspirine 1500 mg / jour pendant 24 mois (n=42)

vs.

Placebo (n=40)

double blind

Parallel groups

Sample size: 42/40

Primary endpoint:

FU duration:

aspirin 75 mg daily (n=1009)

vs.

placebo (n=1026)

double blind

Parallel groups

Sample size: 1009/1026

Primary endpoint: myocardial infarction and sudden death

FU duration: 50 months

aspirin 100mg daily (n=638)

vs.

placebo (n=638)

factoral design with antioxidant capsule

double blind

Factorial plan

Sample size: 638/638

Primary endpoint: Cv events; CHD death+stroke

FU duration: nov 1997 - jul 2001

low-dose aspirin (81 or 100 mg per day) (n=1262)

vs.

no aspirin (n=1277)

open

Parallel groups

Sample size: 1262/1277

Primary endpoint: atherosclerotic events

FU duration: 4.37 y median

aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily) (n=318)

vs.

placebo (n=157)

double blind

Parallel groups

Sample size: 318/157

Primary endpoint: number of microaneurysms

FU duration: 3 y

aspirin 650mg once daily (n=1856)

vs.

placebo (n=1855)

double blind

Parallel groups

Sample size: 1856/1855

Primary endpoint: Mortality from all causes

FU duration: 60 months

oral aspirin 100 mg daily (n=185)

vs.

placebo (n=181)

factorial design with 2nd factor antioxidant vitamins (600mg vit E, 250mg vit C and 20mg beta-caroteen daily) vs placebo

double blind

Factorial plan

Sample size: 185/181

Primary endpoint: cardiovascular death, myocardial infarction, stroke, critical leg ischaemia

FU duration: 20.7 months mean

aspirin 325 mg every other day (n=275)

vs.

placebo (n=258)

double blind

Factorial plan

Sample size: 275/258

Primary endpoint: cardiovascular mortality

FU duration: 5 y

aspirin 100mg daily (n=519)

vs.

control (n=512)

factorial design evaluating aspirin and vitamin E

Initialy, PPP enrolled 4784 patients of whom 1031 had diabetes

open

Factorial plan

Sample size: 519/512

Primary endpoint: CV events

FU duration: 3.6 y

sub group study

aspirin 100mg on alternate days (n=514)

vs.

placebo (n=513)

factorial design of aspirin and vitamin E

trial enrolled 39876 patients of whom 1027 had diabetes (2.6%)

double blind

Parallel groups

Sample size: 514/513

Primary endpoint: cardiovascular event

FU duration: 10.1 y

sub group

all-cause mortality 0.89 [0.74; 1.08]

coronary heart disease mortality 0.94 [0.67; 1.34]

total coronary heart disease events 0.96 [0.75; 1.23]

Cv death 0.93 [0.72; 1.22]

Hemorrhagic Stroke and Intracranial Hemorrhage 1.08 [0.41; 2.84]

non fatal stroke 1.13 [0.72; 1.77]

non fatal MI 0.97 [0.67; 1.41]

Ischemic Stroke 1.50 [0.64; 3.51]

fatal and nonfatal stroke 1.16 [0.80; 1.69]

CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.98 [0.81; 1.19]

Major gastrointestinal bleeding 1.00 [0.47; 2.13]

coronary heart disease mortality 0.64 [0.42; 0.99]

total coronary heart disease events 0.61 [0.51; 0.74]

non fatal MI 0.61 [0.49; 0.75]

CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.83 [0.71; 0.96]

Major gastrointestinal bleeding 1.60 [1.01; 2.52]

all-cause mortality 0.96 [0.79; 1.15]

Cv death 0.98 [0.72; 1.32]

Hemorrhagic Stroke and Intracranial Hemorrhage 1.92 [0.95; 3.85]

non fatal stroke 1.20 [0.91; 1.57]

Ischemic Stroke 1.11 [0.82; 1.49]

fatal and nonfatal stroke 1.21 [0.93; 1.58]

non fatal MI 0.68 [0.53; 0.89]

Major extracranial bleed 1.54 [0.77; 3.08]

all-cause mortality 1.03 [0.79; 1.33]

coronary heart disease mortality 1.06 [0.66; 1.68]

total coronary heart disease events 0.77 [0.58; 1.03]

Cv death 1.24 [0.93; 1.66]

Hemorrhagic Stroke and Intracranial Hemorrhage 2.00 [0.75; 5.31]

non fatal stroke 0.78 [0.50; 1.23]

Ischemic Stroke 0.64 [0.37; 1.09]

fatal and nonfatal stroke 0.69 [0.38; 1.26]

CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.88 [0.74; 1.04]

Major gastrointestinal bleeding 1.54 [0.77; 3.08]

total coronary heart disease events 0.65 [0.49; 0.85]

non fatal MI 0.60 [0.44; 0.80]

myocardial infarction (fatal and non fatal) 0.65 [0.49; 0.85]

CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.86 [0.74; 0.99]

Major extracranial bleed 1.93 [1.43; 2.62]

Gastrointestinal Bleeding 1.94 [1.41; 2.69]

Major gastrointestinal bleeding 2.08 [1.41; 3.07]

all-cause mortality 0.93 [0.79; 1.09]

coronary heart disease mortality 1.00 [0.48; 2.09]

Cv death 0.95 [0.75; 1.20]

Hemorrhagic Stroke and Intracranial Hemorrhage 0.93 [0.45; 1.93]

fatal bleeding 0.87 [0.32; 2.41]

fatal and nonfatal stroke 0.99 [0.79; 1.24]

Gastrointestinal Bleeding 3.47 [1.28; 9.38]

all-cause mortality 0.81 [0.58; 1.13]

coronary heart disease mortality 0.86 [0.39; 1.92]

total coronary heart disease events 0.76 [0.46; 1.25]

Hemorrhagic Stroke and Intracranial Hemorrhage 0.68 [0.11; 4.06]

non fatal MI 0.73 [0.38; 1.41]

Ischemic Stroke 0.95 [0.46; 1.97]

fatal and nonfatal stroke 0.68 [0.36; 1.28]

myocardial infarction (fatal and non fatal) 0.69 [0.39; 1.23]

CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.72 [0.49; 1.04]

Major gastrointestinal bleeding 2.04 [0.51; 8.14]

Ischemic Stroke 0.77 [0.63; 0.94]

fatal and nonfatal stroke 0.83 [0.70; 0.99]

Gastrointestinal Bleeding 1.21 [1.10; 1.33]

Peptic ulcer 1.31 [1.16; 1.49]

Hematuria 1.06 [1.01; 1.11]

Major gastrointestinal bleeding 1.40 [1.07; 1.83]

all-cause mortality 0.95 [0.85; 1.06]

coronary heart disease mortality 1.17 [0.54; 2.52]

total coronary heart disease events 0.97 [0.82; 1.16]

Hemorrhagic Stroke and Intracranial Hemorrhage 1.24 [0.83; 1.88]

non fatal MI 1.02 [0.83; 1.25]

myocardial infarction (fatal and non fatal) 1.03 [0.84; 1.25]

CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.91 [0.81; 1.03]

aspirin 500 mg/d (n=3429)

vs.

no aspirin (n=1710)

open

Parallel groups

Sample size: 3429/1710

Primary endpoint: not defined

FU duration: 5.5 years

aspirin 325 mg every other day (n=11037)

vs.

placebo (n=11034)

factorial design with beta caroten vs placebo

double blind

Parallel groups

Sample size: 11037/11034

Primary endpoint: cardiovascular mortality ?

FU duration: 60.2 months

aspirin 75 mg/d (controlled release) (n=2545)

vs.

placebo (n=2540)

factorial design of aspirin and warfarin (all two vs placebo)

double blind

Factorial plan

Sample size: 2545/2540

Primary endpoint: ischemic heart diseases

FU duration: median 6.8y

aspirin 75 mg daily (n=9399)

vs.

placebo (n=9391)

factorial design with as 2nd factor the comparison of 3 BP targets

Double blind

Factorial plan

Sample size: 9399/9391

Primary endpoint: non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death

FU duration: mean 3.8 y (range 3.3-4.9y)

aspirin 100 mg/d (n=2226)

vs.

no aspirin (open control) (n=2269)

factorial design with other comaprison: vitamin E vs control

Open

Factorial plan

Sample size: 2226/2269

Primary endpoint: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke

FU duration: 3.6 y

aspirin 100mg daily (n=19934)

vs.

placebo (n=19942)

factorial design: vitamin E vs placebo

Double blind

Factorial plan

Sample size: 19934/19942

Primary endpoint: nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular causes

FU duration: 10.1 y mean (range 8.2 to 10.9

fatal or nonfatal coronary event or stroke or revascularisation 1.03 [0.84; 1.27]

major haemorrhage requiring admission to hospital 1.71 [0.99; 2.96]

All cause mortality 0.95 [0.77; 1.17]

Major hemorrhage 1.70 [0.98; 2.94]

all vascular event 1.00 [0.85; 1.17]

gastrointestinal ulcer 1.75 [0.74; 4.16]

fatal hemorrhagic stroke 1.00 [0.20; 4.95]

non fatal hemorrhagic stroke 2.00 [0.18; 22.04]

aspirin 100mg daily (n=1675)

vs.

placebo (n=1675)

double blind

Parallel groups

Sample size: 1675/1675

Primary endpoint: fatal or nonfatal coronary event or stroke or revascularisation

FU duration: 8.2 y (mean)

IDM fatal 0.62 [0.44; 0.88]

IDM totaux 0.63 [0.47; 0.85]

Mortalité totale 0.81 [0.63; 1.06]

AVC fatal 0.95 [0.69; 1.31]

AVC non fatal 1.38 [0.55; 3.42]

IDM non fatal 0.67 [0.37; 1.21]

vascular event 0.90 [0.63; 1.29]

Clopidogrel 75 mg (n=3223)

vs.

Aspirine 325 mg (n=3229)

Effectifs correspondant à la strate AOMI

double blind

Parallel groups

Sample size: 3223/3229

Primary endpoint: Critère composite

FU duration: 1.91 y

clopidogrel 75 mg once daily for two years (n=498)

vs.

Aspirin 160 mg once daily for two years (n=503)

platelet function was also assessed at randomization with the PFA100 method and platelet aggregometry

open

Parallel groups

Sample size: 498/503

Primary endpoint: all-cause death, nonfatal MI, ischemic stroke, and unstable angina

FU duration:

Non fatal MI 0.84 [0.70; 1.00]

MI,stroke or CVdeath 0.92 [0.84; 1.00]

Death from any cause 0.98 [0.87; 1.10]

Death from cardiovascular causes 0.92 [0.80; 1.07]

severe bleeding 0.88 [0.70; 1.12]

non fatal stroke 0.94 [0.82; 1.07]

clopidogrel 75 mg once daily (n=9599)

vs.

aspirin 325 mg once daily (n=9586)

Double blind

Parallel groups

Sample size: 9599/9586

Primary endpoint: ischaemic stroke, myocardial infarction, or vascular death

FU duration: mean 1.91 years

non fatal stroke 0.81 [0.65; 1.00]

moderate bleeding 1.62 [1.27; 2.08]

nonfatal Ischemic stroke 0.82 [0.66; 1.04]

Death from any cause 0.99 [0.86; 1.14]

Death from cardiovascular causes 1.04 [0.87; 1.24]

severe bleeding 1.25 [0.97; 1.61]

Non fatal MI 0.92 [0.74; 1.15]

fatal bleeding 1.53 [0.83; 2.82]

MI,stroke or CVdeath 0.93 [0.83; 1.04]

clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) (n=7802)

vs.

placebo plus low-dose aspirin (n=7801)

Double blind

Parallel groups

Sample size: 7802/7801

Primary endpoint: myocardial infarction, stroke or death from cardiovasculare causes

FU duration: median 28 months

Stroke 0.63 [0.25; 1.58]

Stroke 0.61 [0.35; 1.05]

vascular death ∞ [NaN; ∞]

Non fatal stroke ∞ [NaN; ∞]

Non fatal MI 0.75 [0.18; 3.07]

non vascular death NaN [NaN; NaN]

vascular event 1.25 [0.37; 4.21]

vascular death ∞ [NaN; ∞]

Non fatal stroke NaN [NaN; NaN]

Non fatal MI NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

vascular event ∞ [NaN; ∞]

vascular death NaN [NaN; NaN]

Non fatal stroke NaN [NaN; NaN]

Non fatal MI NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

vascular event NaN [NaN; NaN]

Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810)

vs.

Placebo (n=406)

Double blind

Parallel groups

Sample size: 810/406

Primary endpoint: No primary outcome clearly defined

FU duration: 41 months (mean)

part of 3-group trial

Aspirin (330 mg) + dipyridamole (75 mg) 3x/d (n=1563)

vs.

Placebo (n=1565)

Double blind

Parallel groups

Sample size: 1563/1565

Primary endpoint: No primary outcome clearly defined

FU duration: 23.4 months

Aspirine Dipyridamole 330 mg / j 225 mg / j (n=80)

vs.

Placebo (n=80)

double blind

Parallel groups

Sample size: 80/80

Primary endpoint: Score de progression de l’athérosclérose

FU duration:

Aspirine Dipyridamole 990 mg / j 225 mg /j (n=100)

vs.

Placebo (n=100)

double blind

Parallel groups

Sample size: 100/100

Primary endpoint: Progression de l’athérosclérose

FU duration:

Aspirine + Dipyridamole 975 mg / j 225 mg /j (n=110)

vs.

Placebo (n=121)

double blind

Parallel groups

Sample size: 110/121

Primary endpoint: Mortalité due à une pathologie vasculaire athérosclérotique ou amputation pour gangrène au membre op

FU duration: 46 months

dipyridamole 150mg daily (n=30)

vs.

placebo (n=30)

double-blind

parallel groups

Sample size: 30/30

Primary endpoint: not defined

FU duration: 6 months

dipyridamole 225mg daily (n=14)

vs.

placebo (n=13)

double-blind

parallel groups

Sample size: 14/13

Primary endpoint: not defined

FU duration: 5 months

dipyridamole 150mg daily (n=28)

vs.

placebo (n=28)

double blind

parallel groups

Sample size: 28/28

Primary endpoint: not defined

FU duration: 7 months

Dipyridamole 200mg daily (n=26)

vs.

placebo (n=22)

double blind

parallel groups

Sample size: 26/22

Primary endpoint: not defined

FU duration: 2-7 months

Dipyridamole 37.5mg (n=14)

vs.

placebo (n=14)

double-blind

cross-over

Sample size: 14/14

Primary endpoint: not defined

FU duration: 0.5 months

dipyridamole 37.5 mg and 100mg daily (n=13)

vs.

placebo (n=13)

double-blind

parallel groups

Sample size: 13/13

Primary endpoint: not defined

FU duration: 0.5 months

dipyridamole 100mg daily (n=19)

vs.

placebo (n=19)

double blind

parallel groups

Sample size: 19/19

Primary endpoint: not defined

FU duration: >3 months

Dipyridamole 100mg daily (n=17)

vs.

placebo (n=17)

double-blind

parallel groups

Sample size: 17/17

Primary endpoint: not defined

FU duration: 0.5 months

dipyridamole 150mg daily (n=20)

vs.

placebo (n=16)

double-blind

parallel groups

Sample size: 20/16

Primary endpoint: not defined

FU duration: 1.5 months

Dipyridamole 200mg daily (n=24)

vs.

placebo (n=24)

double-blind

parallel groups

Sample size: 24/24

Primary endpoint: not defined

FU duration: 1 months

Death or nonfatal MI 1.05 [0.84; 1.30]

Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810)

vs.

Aspirin (324 mg) 3x/d (n=810)

Double blind

Parallel groups

Sample size: 810/810

Primary endpoint: No primary outcome clearly defined

FU duration: 41 months

part of 3-group trial

Ketanserin 40 mg / j pdt 1 mois 80 mg / j ensuite (n=1930)

vs.

Placebo (n=1969)

double blind

Parallel groups

Sample size: 1930/1969

Primary endpoint: IDM, AVC majeur, amputation au dessus de la cheville pour des raisons autres que tumorales ou trauma

FU duration: 1 y

Ketanserin 60 mg / j pdt 1 mois 120 mg / j ensuite (n=17)

vs.

Placebo (n=18)

double blind

Parallel groups

Sample size: 17/18

Primary endpoint: Périmètre de marche

FU duration: 15 months

Ketanserin 60 mg / j pdt 2 semaines 120 mg / j ensuite (n=79)

vs.

Placebo (n=86)

double blind

Parallel groups

Sample size: 79/86

Primary endpoint: Périmètre de marche

FU duration: 6 months

CV death 0.00 [0.00; NaN]

non fatal MI 0.00 [0.00; NaN]

CV events (fatal and non fatal) 0.00 [0.00; NaN]

Picotamide 600 mg / j (n=1150)

vs.

Placebo (n=1154)

double blind

Parallel groups

Sample size: 1150/1154

Primary endpoint: Mortalité vasculaire et non vasculaire, IDM fatal ou non, AVC fatal ou non, amputation au dessus de

FU duration: 18 months

Picotamide 900 mg / j (n=10)

vs.

Placebo (n=10)

double blind

Parallel groups

Sample size: 10/10

Primary endpoint: Paramètres hémodynamiques, de coagulation, d’activité plaquettaire

FU duration: 18 months

Picotamide 900 mg / j (n=20)

vs.

Placebo (n=20)

double blind

Parallel groups

Sample size: 20/20

Primary endpoint: Périmètres de marche, paramètres sanguins

FU duration: 6 months

picotamide 300 mg TID (n=25)

vs.

placebo (n=25)

double blind

Parallel groups

Sample size: 25/25

Primary endpoint: not unique (carotid atherosclerotic lesions)

FU duration: 24 months

All cause mortality ∞ [NaN; ∞]

CV death ∞ [NaN; ∞]

non fatal MI 1.00 [0.05; 18.57]

CV events (fatal and non fatal) 2.07 [0.41; 10.46]

sulfinyrazone (n=30)

vs.

(n=31)

Parallel groups

Sample size: 30/31

Primary endpoint:

FU duration: 32 months

Suloctidil 200 mg / j (n=15)

vs.

Placebo (n=15)

double blind

Parallel groups

Sample size: 15/15

Primary endpoint: Périmètre de marche

FU duration: 2 months

Suloctidil 200 mg / j (n=-9)

vs.

Placebo (n=-9)

double blind

Parallel groups

Sample size: -9/-9

Primary endpoint: Périmètre de marche

FU duration: 6 months

Suloctidil 300 mg / j (n=18)

vs.

Placebo (n=22)

double blind

Parallel groups

Sample size: 18/22

Primary endpoint: Périmètre de marche, pression à la cheville, flux sanguin musculaire

FU duration: 6 months

Suloctidil 300 mg / j (n=20)

vs.

Placebo (n=20)

double blind

Parallel groups

Sample size: 20/20

Primary endpoint: Périmètre de marche, pression à la cheville, flux sanguin musculaire

FU duration: 2.75 y

ticagrelor (90 mg twice daily) (n=-9)

vs.

clopidogrel (75 mg once daily) (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 30 months (median)

Stroke (any) 0.75 [0.57; 0.98]

myocardial infarction 0.85 [0.73; 0.99]

all vascular event 0.85 [0.75; 0.95]

CV death, MI, stroke 0.85 [0.75; 0.95]

Major hemorrhage 2.16 [1.56; 2.99]

All cause mortality 0.89 [0.76; 1.04]

death from CHD 0.81 [0.63; 1.04]

cardiovascular death 0.83 [0.68; 1.01]

fatal bleeding 0.92 [0.41; 2.08]

Intracranial haemorrhage 1.10 [0.67; 1.81]

death from CHD 0.74 [0.57; 0.96]

myocardial infarction 0.82 [0.70; 0.95]

all vascular event 0.85 [0.76; 0.96]

CV death, MI, stroke 0.85 [0.76; 0.96]

Major hemorrhage 2.36 [1.72; 3.24]

All cause mortality 1.00 [0.86; 1.16]

cardiovascular death 0.87 [0.71; 1.06]

fatal bleeding 0.50 [0.19; 1.33]

Intracranial haemorrhage 1.26 [0.73; 2.18]

Stroke (any) 0.82 [0.63; 1.07]

ticagrelor at a dose of 60 mg twice daily (n=7045)

vs.

placebo (n=7067)

double-blind

Parallel groups

Sample size: 7045/7067

Primary endpoint: cardiovascular death, myocardial

FU duration: 2.75 y (median)

ticagrelor at a dose of 90 mg twice daily (n=7050)

vs.

(n=7067)

double-blind

Sample size: 7050/7067

Primary endpoint: cardiovascular death, myocardial

FU duration: 2.75 y (median)

vascular death NaN [NaN; NaN]

Non fatal stroke NaN [NaN; NaN]

Non fatal MI NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

vascular event NaN [NaN; NaN]

All cause mortality NaN [NaN; NaN]

CV death NaN [NaN; NaN]

non fatal MI 0.00 [0.00; NaN]

CV events (fatal and non fatal) 0.00 [0.00; NaN]

All cause mortality 1.05 [0.07; 16.24]

CV death 1.05 [0.07; 16.24]

non fatal MI NaN [NaN; NaN]

CV events (fatal and non fatal) 0.53 [0.05; 5.57]

All cause mortality 0.73 [0.17; 3.24]

CV death 0.49 [0.04; 5.35]

non fatal MI 0.33 [0.03; 3.84]

CV events (fatal and non fatal) 0.56 [0.17; 1.88]

All cause mortality NaN [NaN; NaN]

CV death NaN [NaN; NaN]

non fatal MI 0.00 [0.00; NaN]

CV events (fatal and non fatal) 0.00 [0.00; NaN]

All cause mortality ∞ [NaN; ∞]

CV death ∞ [NaN; ∞]

non fatal MI NaN [NaN; NaN]

CV events (fatal and non fatal) ∞ [NaN; ∞]

Ticlopidine 500 mg/j (n=304)

vs.

Placebo (n=311)

double blind

Parallel groups

Sample size: 304/311

Primary endpoint: Mortalité subite, IDM, AVC, intervention chirurgicale liée à une aggravation clinique

FU duration:

Ticlopidine 500 mg/j (n=93)

vs.

Placebo (n=100)

double blind

Parallel groups

Sample size: 93/100

Primary endpoint: Taille / cicatrisation des ulcères

FU duration: 6 semaines

Ticlopidine 500 mg/j (n=33)

vs.

Placebo (n=32)

double blind

Parallel groups

Sample size: 33/32

Primary endpoint: Périmètre de marche, pressionsystolique à la cheville

FU duration: 1 y

Ticlopidine 500 mg/j (n=57)

vs.

Placebo (n=57)

double blind

Parallel groups

Sample size: 57/57

Primary endpoint: Score de progression de l’athérosclérose

FU duration:

Ticlopidine 500 mg/j (n=100)

vs.

Placebo (n=103)

double blind

Parallel groups

Sample size: 100/103

Primary endpoint: Périmètre de marche

FU duration: 6 months

Ticlopidine 500 mg/j (n=66)

vs.

Placebo (n=66)

double blind

Parallel groups

Sample size: 66/66

Primary endpoint: Périmètre de marche

FU duration: 1 y

Ticlopidine 500 mg/j (n=83)

vs.

Placebo (n=86)

double blind

Parallel groups

Sample size: 83/86

Primary endpoint: Périmètre de marche

FU duration: 6 months

randomisation centralisée

Ticlopidine 500 mg/j (n=76)

vs.

Placebo (n=75)

double blind

Parallel groups

Sample size: 76/75

Primary endpoint: Périmètre de marche

FU duration: 21 months

Ticlopidine 500 mg/j (n=346)

vs.

Placebo (n=341)

double blind

Parallel groups

Sample size: 346/341

Primary endpoint: IDM, AVC, AIT

FU duration: 5.6 y

Ticlopidine : 100 -500 mg / jour pendant 2 mois. (n=30)

vs.

Placebo (n=30)

double blind

Parallel groups

Sample size: 30/30

Primary endpoint:

FU duration:

Ticlopidine : 500 mg pendant 4 mois (n=19)

vs.

Placebo (n=19)

double blind

Parallel groups

Sample size: 19/19

Primary endpoint:

FU duration:

ticlopidine 500 mg daily (n=21)

vs.

placebo (n=17)

double blind

parallel groups

Sample size: 21/17

Primary endpoint: not defined

FU duration: 2m

ticlopidine 100, 250, 500 mg (n=20)

vs.

(n=8)

Parallel groups

Sample size: 20/8

Primary endpoint:

FU duration: 2 months

ticlopidine 500mg (n=38)

vs.

(n=40)

Parallel groups

Sample size: 38/40

Primary endpoint:

FU duration: 12 months

ticlopidine 500mg (n=220)

vs.

(n=215)

Parallel groups

Sample size: 220/215

Primary endpoint:

FU duration: 32m

ticlopidine 500mg/d (n=49)

vs.

placebo (n=51)

double blind

Parallel groups

Sample size: 49/51

Primary endpoint: evolution of retinopathy

FU duration: 48 months

ticlopidine 500mg daily (n=12)

vs.

placebo (n=11)

double blind

Parallel groups

Sample size: 12/11

Primary endpoint:

FU duration: 12 months

Cloricromène : 100 mg, 2 fois / jour / voie orale + aspirine : 160 mg / jour pendant 6 mois . (n=81)

vs.

placebo + aspirine: 160 mg/ jour pendant 6 mois. (n=78)

double blind

Parallel groups

Sample size: 81/78

Primary endpoint: périmètre de marche ( maximal, sans douleur)

FU duration: 6 months

Tous les pts ont été admis dans une période de run-in de 3 semaines en simple aveugle : avec prise d'1 cp de placebo, 2 fois / jour, afin d'évaluer leur éligiblité dans la période en double aveugle de l'essai. Randomisation centralisée

myocardial infarction 0.84 [0.75; 0.93]

all vascular event 0.87 [0.80; 0.94]

CV death, MI, stroke 0.87 [0.81; 0.95]

major haemorrhage requiring admission to hospital 1.42 [1.32; 1.52]

Major hemorrhage 1.45 [1.21; 1.73]

Intracranial haemorrhage 1.92 [1.38; 2.68]

All cause mortality 0.96 [0.85; 1.07]

cardiovascular death 0.89 [0.76; 1.05]

fatal bleeding 1.45 [0.82; 2.56]

Stroke (any) 0.97 [0.83; 1.13]

all vascular event 0.84 [0.76; 0.93]

all vascular event 0.81 [0.73; 0.90]

Major hemorrhage 1.29 [1.02; 1.63]

All cause mortality 0.93 [0.79; 1.09]

fatal bleeding 1.56 [0.45; 5.41]

Intracranial haemorrhage 1.54 [0.54; 4.34]

fatal hemorrhagic stroke 1.53 [0.95; 2.46]

net benefit 0.92 [0.36; 2.33]

vorapaxar (SCH 530348) 2.5-mg daily (n=13225)

vs.

placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel) (n=13244)

trial was discontinued in patients who experienced a stroke. The study drug will be continued in patients with previous MI or peripheral disease

double-blind

Parallel groups

Sample size: 13225/13244

Primary endpoint: CV death, MI, stroke, urgent revascularization

FU duration: 2.5 y (median)

vorapaxar (SCH 530348) 2.5-mg daily (n=20699)

vs.

placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel) (n=0)

trial was discontinued in patients who experienced a stroke. The study drug will be continued in patients with previous MI or peripheral disease

double-blind

Parallel groups

Sample size: 20699/0

Primary endpoint: CV death, MI, stroke, urgent revascularization

FU duration: 2.5 y (median)

vorapaxar (SCH 530348) 2.5-mg daily (n=8898)

vs.

placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel) (n=8881)

trial was discontinued in patients who experienced a stroke. The study drug will be continued in patients with previous MI or peripheral disease

double-blind

Parallel groups

Sample size: 8898/8881

Primary endpoint: CV death, MI, stroke, urgent revascularization

FU duration: 2.5 y (median)

All cause mortality 0.93 [0.72; 1.21]

CHD death 1.35 [0.82; 2.21]

CHD events (fatal and non fatal) 1.10 [0.83; 1.45]

CV death 1.23 [0.80; 1.89]

fatal MI 1.35 [0.82; 2.21]

fatal stroke 0.89 [0.35; 2.29]

non fatal MI 0.98 [0.69; 1.40]

stroke (fatal and non fatal) 0.74 [0.49; 1.12]

CV events (fatal and non fatal) 0.99 [0.79; 1.25]

peripheral artery disease 0.91 [0.70; 1.17]

stable angina 0.90 [0.66; 1.22]

CV death 0.10 [0.01; 0.79]

CHD death 0.00 [0.00; NaN]

CHD events (fatal and non fatal) 0.81 [0.50; 1.32]

fatal MI 0.00 [0.00; NaN]

fatal stroke 0.20 [0.02; 1.73]

non fatal MI 1.35 [0.57; 3.19]

stroke (fatal and non fatal) 0.89 [0.54; 1.46]

CV events (fatal and non fatal) 0.80 [0.59; 1.09]

peripheral artery disease 0.64 [0.25; 1.66]

stable angina 1.10 [0.49; 2.49]

unstable angina 0.40 [0.13; 1.29]

non fatal MI 4.20 [1.10; 16.10]

All cause mortality 0.49 [0.13; 1.95]

CV death 0.49 [0.10; 2.42]

CV events (fatal and non fatal) 1.48 [0.68; 3.22]

CHD events (fatal and non fatal) 0.85 [0.73; 1.00]

All cause mortality 0.93 [0.81; 1.06]

CV death 0.92 [0.79; 1.07]

non fatal MI 0.78 [0.54; 1.11]

stroke (fatal and non fatal) 1.18 [0.88; 1.58]

CV events (fatal and non fatal) 0.95 [0.83; 1.07]

CHD events (fatal and non fatal) 0.40 [0.20; 0.79]

All cause mortality 1.23 [0.69; 2.19]

CHD events (fatal and non fatal) 0.49 [0.17; 1.43]

CV death 1.23 [0.49; 3.10]

revascularization procedure 0.79 [0.31; 1.98]

stroke (fatal and non fatal) 0.89 [0.36; 2.17]

all MI 0.49 [0.17; 1.43]

CV events (fatal and non fatal) 0.90 [0.50; 1.62]

peripheral artery disease 0.83 [0.38; 1.85]

stable angina 0.80 [0.39; 1.65]

stroke (fatal and non fatal) 0.48 [0.26; 0.88]

CHD events (fatal and non fatal) 1.50 [0.91; 2.47]

all MI 1.50 [0.91; 2.47]

CV events (fatal and non fatal) 0.93 [0.67; 1.31]

aspirin 100mg daily (n=638)

vs.

placebo (n=638)

factoral design with antioxidant capsule

double blind

Factorial plan

Sample size: 638/638

Primary endpoint: Cv events; CHD death+stroke

FU duration: nov 1997 - jul 2001

low-dose aspirin (81 or 100 mg per day) (n=1262)

vs.

no aspirin (n=1277)

open

Parallel groups

Sample size: 1262/1277

Primary endpoint: atherosclerotic events

FU duration: 4.37 y median

aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily) (n=318)

vs.

placebo (n=157)

double blind

Parallel groups

Sample size: 318/157

Primary endpoint: number of microaneurysms

FU duration: 3 y

aspirin 650mg once daily (n=1856)

vs.

placebo (n=1855)

double blind

Parallel groups

Sample size: 1856/1855

Primary endpoint: Mortality from all causes

FU duration: 60 months

aspirin 325 mg every other day (n=275)

vs.

placebo (n=258)

double blind

Factorial plan

Sample size: 275/258

Primary endpoint: cardiovascular mortality

FU duration: 5 y

aspirin 100mg daily (n=519)

vs.

control (n=512)

factorial design evaluating aspirin and vitamin E

Initialy, PPP enrolled 4784 patients of whom 1031 had diabetes

open

Factorial plan

Sample size: 519/512

Primary endpoint: CV events

FU duration: 3.6 y

sub group study

aspirin 100mg on alternate days (n=514)

vs.

placebo (n=513)

factorial design of aspirin and vitamin E

trial enrolled 39876 patients of whom 1027 had diabetes (2.6%)

double blind

Parallel groups

Sample size: 514/513

Primary endpoint: cardiovascular event

FU duration: 10.1 y

sub group

CV death 0.00 [0.00; NaN]

non fatal MI 0.00 [0.00; NaN]

CV events (fatal and non fatal) 0.00 [0.00; NaN]

picotamide 300 mg TID (n=25)

vs.

placebo (n=25)

double blind

Parallel groups

Sample size: 25/25

Primary endpoint: not unique (carotid atherosclerotic lesions)

FU duration: 24 months

All cause mortality ∞ [NaN; ∞]

CV death ∞ [NaN; ∞]

non fatal MI 1.00 [0.05; 18.57]

CV events (fatal and non fatal) 2.07 [0.41; 10.46]

sulfinyrazone (n=30)

vs.

(n=31)

Parallel groups

Sample size: 30/31

Primary endpoint:

FU duration: 32 months

All cause mortality NaN [NaN; NaN]

CV death NaN [NaN; NaN]

non fatal MI 0.00 [0.00; NaN]

CV events (fatal and non fatal) 0.00 [0.00; NaN]

All cause mortality 1.05 [0.07; 16.24]

CV death 1.05 [0.07; 16.24]

non fatal MI NaN [NaN; NaN]

CV events (fatal and non fatal) 0.53 [0.05; 5.57]

All cause mortality 0.73 [0.17; 3.24]

CV death 0.49 [0.04; 5.35]

non fatal MI 0.33 [0.03; 3.84]

CV events (fatal and non fatal) 0.56 [0.17; 1.88]

All cause mortality NaN [NaN; NaN]

CV death NaN [NaN; NaN]

non fatal MI 0.00 [0.00; NaN]

CV events (fatal and non fatal) 0.00 [0.00; NaN]

All cause mortality ∞ [NaN; ∞]

CV death ∞ [NaN; ∞]

non fatal MI NaN [NaN; NaN]

CV events (fatal and non fatal) ∞ [NaN; ∞]

ticlopidine 100, 250, 500 mg (n=20)

vs.

(n=8)

Parallel groups

Sample size: 20/8

Primary endpoint:

FU duration: 2 months

ticlopidine 500mg (n=38)

vs.

(n=40)

Parallel groups

Sample size: 38/40

Primary endpoint:

FU duration: 12 months

ticlopidine 500mg (n=220)

vs.

(n=215)

Parallel groups

Sample size: 220/215

Primary endpoint:

FU duration: 32m

ticlopidine 500mg/d (n=49)

vs.

placebo (n=51)

double blind

Parallel groups

Sample size: 49/51

Primary endpoint: evolution of retinopathy

FU duration: 48 months

ticlopidine 500mg daily (n=12)

vs.

placebo (n=11)

double blind

Parallel groups

Sample size: 12/11

Primary endpoint:

FU duration: 12 months

total coronary heart disease events 0.65 [0.49; 0.85]

non fatal MI 0.60 [0.44; 0.80]

myocardial infarction (fatal and non fatal) 0.65 [0.49; 0.85]

CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.86 [0.74; 0.99]

Major extracranial bleed 1.93 [1.43; 2.62]

Gastrointestinal Bleeding 1.94 [1.41; 2.69]

Major gastrointestinal bleeding 2.08 [1.41; 3.07]

all-cause mortality 0.93 [0.79; 1.09]

coronary heart disease mortality 1.00 [0.48; 2.09]

Cv death 0.95 [0.75; 1.20]

Hemorrhagic Stroke and Intracranial Hemorrhage 0.93 [0.45; 1.93]

fatal bleeding 0.87 [0.32; 2.41]

fatal and nonfatal stroke 0.99 [0.79; 1.24]

aspirin 75 mg daily (n=9399)

vs.

placebo (n=9391)

factorial design with as 2nd factor the comparison of 3 BP targets

Double blind

Factorial plan

Sample size: 9399/9391

Primary endpoint: non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death

FU duration: mean 3.8 y (range 3.3-4.9y)

MACE 0.00 [0.00; NaN]

MACE 1.00 [0.15; 6.55]

MACE 1.97 [0.18; 21.56]

MACE 0.68 [0.11; 3.99]

MACE 0.00 [0.00; NaN]

MACE 0.00 [0.00; NaN]

MACE 0.00 [0.00; NaN]